Avizakimab, formerly known as BOS161721, represents a novel medicinal approach to treating immune-mediated conditions . This antibody medication selectively targets interleukin-18 , a crucial cytokine https://aishanrns205056.blognody.com/50943782/avizakimab-a-thorough-investigation-into-bos161721-s-potential